|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
[Antimycin A co-treated with Deoxyglucose] results in increased expression of BAX protein; Quercetin inhibits the reaction [[Antimycin A co-treated with Deoxyglucose] results in increased expression of BAX protein] |
CTD |
PMID:25087994 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
[Antimycin A co-treated with Deoxyglucose] results in decreased phosphorylation of MTOR protein; Quercetin promotes the reaction [[Antimycin A co-treated with Deoxyglucose] results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:25087994 |
|
NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888
|
|
G |
NOS3 |
nitric oxide synthase 3 |
decreases expression |
EXP |
Deoxyglucose results in decreased expression of NOS3 mRNA |
CTD |
PMID:11382920 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
|
G |
ATP7B |
ATPase copper transporting beta |
multiple interactions |
EXP |
Cyclic AMP inhibits the reaction [Copper binds to ATP7B protein] |
CTD |
PMID:21084060 |
|
NCBI chr11:15,892,549...15,942,070
Ensembl chr11:15,876,612...15,942,064
|
|
G |
CALCB |
calcitonin-related polypeptide beta |
increases abundance |
EXP |
CALCA protein results in increased abundance of Cyclic AMP |
CTD |
PMID:18463244 |
|
NCBI chr 2:44,043,135...44,048,651
|
|
G |
DUOX2 |
dual oxidase 2 |
increases expression |
EXP |
Cyclic AMP results in increased expression of DUOX2 mRNA |
CTD |
PMID:10601291 |
|
NCBI chr 1:126,620,468...126,641,406
Ensembl chr 1:126,620,510...126,641,406
|
|
G |
GCG |
glucagon |
affects response to substance increases abundance |
EXP |
Cyclic AMP affects the susceptibility to GCG protein GCG protein results in increased abundance of Cyclic AMP |
CTD |
PMID:6253273 |
|
NCBI chr15:68,800,557...68,810,268
Ensembl chr15:68,800,560...68,810,242
|
|
G |
GNRH1 |
gonadotropin releasing hormone 1 |
multiple interactions increases abundance |
EXP |
[Cobalt binds to GNRH1 protein] which results in increased abundance of Cyclic AMP GNRH1 protein results in increased abundance of Cyclic AMP |
CTD |
PMID:15833593 |
|
NCBI chr14:9,442,971...9,447,521
Ensembl chr14:9,442,971...9,453,035
|
|
|
G |
PDE5A |
phosphodiesterase 5A |
increases degradation |
EXP |
PDE5 protein results in increased degradation of Cyclic GMP |
CTD |
PMID:18669600 |
|
NCBI chr 8:104,270,858...104,420,955
Ensembl chr 8:104,270,881...104,420,953
|
|
G |
PDE6C |
phosphodiesterase 6C |
increases degradation |
EXP |
PDE6C protein results in increased degradation of Cyclic GMP |
CTD |
PMID:18669600 |
|
NCBI chr14:105,010,974...105,122,628
Ensembl chr14:105,050,691...105,122,421
|
|
G |
PRKG1 |
protein kinase cGMP-dependent 1 |
increases activity |
EXP |
Cyclic GMP results in increased activity of PRKG1 protein |
CTD |
PMID:18037907 |
|
NCBI chr14:97,558,531...98,793,080
Ensembl chr14:97,558,533...98,793,010
|
|
|
G |
MYL9 |
myosin light chain 9 |
decreases phosphorylation multiple interactions |
EXP |
Adenosine results in decreased phosphorylation of MYL9 protein 8-phenyltheophylline inhibits the reaction [Adenosine results in decreased phosphorylation of MYL9 protein] |
CTD |
PMID:10942722 |
|
NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293
|
|
|
G |
ACACA |
acetyl-CoA carboxylase alpha |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of ACACA mRNA MLXIP protein affects the reaction [Glucose results in increased expression of ACACA mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr12:38,580,916...38,875,067
Ensembl chr12:38,581,457...38,824,712
|
|
G |
FASN |
fatty acid synthase |
multiple interactions increases expression |
EXP |
MLXIP protein affects the reaction [Glucose results in increased expression of FASN mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr12:922,405...937,560
Ensembl chr12:920,509...937,561
|
|
G |
INS |
insulin |
multiple interactions increases transport |
EXP |
INS protein promotes the reaction [AZ 002 results in increased uptake of Glucose]; oxophenylarsine inhibits the reaction [INS protein results in increased transport of Glucose]; Sirolimus inhibits the reaction [Glucose results in increased secretion of INS protein] |
CTD |
PMID:8048502 PMID:8699633 PMID:20622751 |
|
NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
|
|
G |
LOC102165256 |
V-type proton ATPase subunit G 1 pseudogene |
decreases expression |
EXP |
Glucose results in decreased expression of ATP6V1G1 mRNA |
CTD |
PMID:16313995 |
|
NCBI chr 7:19,272,032...19,272,926
|
|
G |
MLXIP |
MLX interacting protein |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of MLXIP mRNA Glucose promotes the reaction [T0901317 results in increased expression of MLXIP mRNA]; MLXIP protein affects the reaction [Glucose results in increased expression of ACACA mRNA]; MLXIP protein affects the reaction [Glucose results in increased expression of FASN mRNA]; MLXIP protein affects the reaction [Glucose results in increased expression of SREBF1 mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr14:30,575,098...30,646,275
Ensembl chr14:30,577,661...30,646,243
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
EXP |
Kangen-karyu inhibits the reaction [Glucose results in increased expression of NOS2 protein] |
CTD |
PMID:16949779 |
|
NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
multiple interactions increases expression |
EXP |
T0901317 promotes the reaction [Glucose results in increased expression of NR1H3 mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr 2:15,315,283...15,336,785
Ensembl chr 2:15,315,282...15,334,820
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
Kangen-karyu inhibits the reaction [Glucose results in increased expression of PTGS2 protein] |
CTD |
PMID:16949779 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
SLC2A1 |
solute carrier family 2 member 1 |
increases transport |
EXP |
SLC2A1 protein results in increased transport of Glucose |
CTD |
PMID:12081571 |
|
NCBI chr 6:168,535,398...168,561,170
Ensembl chr 6:168,535,440...168,560,867
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions increases expression |
EXP |
MLXIP protein affects the reaction [Glucose results in increased expression of SREBF1 mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr12:60,733,967...60,750,951
Ensembl chr12:60,733,907...60,751,267
|
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
increases expression multiple interactions |
EXP |
Adenosine Triphosphate results in increased expression of BCL2 protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of BCL2 protein] |
CTD |
PMID:17997382 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP8 |
caspase 8 |
increases activity multiple interactions |
EXP |
Adenosine Triphosphate results in increased activity of CASP8 protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased activity of CASP8 protein] |
CTD |
PMID:17997382 |
|
NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
|
|
G |
CYCS |
cytochrome c, somatic |
affects localization multiple interactions |
EXP |
Adenosine Triphosphate affects the localization of CYCS protein [Calcium co-treated with Phosphates co-treated with Adenosine Triphosphate] affects the localization of CYCS protein; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate affects the localization of CYCS protein] |
CTD |
PMID:16489745 PMID:17997382 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
MYL9 |
myosin light chain 9 |
decreases phosphorylation multiple interactions |
EXP |
Adenosine Triphosphate results in decreased phosphorylation of MYL9 protein 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]]; Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:10942722 |
|
NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293
|
|
G |
TNF |
tumor necrosis factor |
increases expression multiple interactions |
EXP |
Adenosine Triphosphate results in increased expression of TNF protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of TNF protein] |
CTD |
PMID:17997382 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
ATP1A1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
Bucladesine results in increased expression of ATP1A1 protein |
CTD |
PMID:28438630 |
|
NCBI chr 4:104,353,506...104,384,321
Ensembl chr 4:104,353,508...104,384,547
|
|
|
G |
ACACA |
acetyl-CoA carboxylase alpha |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of ACACA mRNA MLXIP protein affects the reaction [Glucose results in increased expression of ACACA mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr12:38,580,916...38,875,067
Ensembl chr12:38,581,457...38,824,712
|
|
G |
FASN |
fatty acid synthase |
multiple interactions increases expression |
EXP |
MLXIP protein affects the reaction [Glucose results in increased expression of FASN mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr12:922,405...937,560
Ensembl chr12:920,509...937,561
|
|
G |
INS |
insulin |
multiple interactions increases transport |
EXP |
INS protein promotes the reaction [AZ 002 results in increased uptake of Glucose]; oxophenylarsine inhibits the reaction [INS protein results in increased transport of Glucose]; Sirolimus inhibits the reaction [Glucose results in increased secretion of INS protein] |
CTD |
PMID:8048502 PMID:8699633 PMID:20622751 |
|
NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
|
|
G |
LOC102165256 |
V-type proton ATPase subunit G 1 pseudogene |
decreases expression |
EXP |
Glucose results in decreased expression of ATP6V1G1 mRNA |
CTD |
PMID:16313995 |
|
NCBI chr 7:19,272,032...19,272,926
|
|
G |
MLXIP |
MLX interacting protein |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of MLXIP mRNA Glucose promotes the reaction [T0901317 results in increased expression of MLXIP mRNA]; MLXIP protein affects the reaction [Glucose results in increased expression of ACACA mRNA]; MLXIP protein affects the reaction [Glucose results in increased expression of FASN mRNA]; MLXIP protein affects the reaction [Glucose results in increased expression of SREBF1 mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr14:30,575,098...30,646,275
Ensembl chr14:30,577,661...30,646,243
|
|
G |
NOS2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of NOS2 protein Kangen-karyu inhibits the reaction [Glucose results in increased expression of NOS2 protein] |
CTD |
PMID:16949779 |
|
NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
multiple interactions increases expression |
EXP |
T0901317 promotes the reaction [Glucose results in increased expression of NR1H3 mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr 2:15,315,283...15,336,785
Ensembl chr 2:15,315,282...15,334,820
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of PTGS2 protein Kangen-karyu inhibits the reaction [Glucose results in increased expression of PTGS2 protein] |
CTD |
PMID:16949779 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
SLC2A1 |
solute carrier family 2 member 1 |
increases transport |
EXP |
SLC2A1 protein results in increased transport of Glucose |
CTD |
PMID:12081571 |
|
NCBI chr 6:168,535,398...168,561,170
Ensembl chr 6:168,535,440...168,560,867
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions increases expression |
EXP |
MLXIP protein affects the reaction [Glucose results in increased expression of SREBF1 mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr12:60,733,967...60,750,951
Ensembl chr12:60,733,907...60,751,267
|
|
|
G |
ACACA |
acetyl-CoA carboxylase alpha |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of ACACA mRNA MLXIP protein affects the reaction [Glucose results in increased expression of ACACA mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr12:38,580,916...38,875,067
Ensembl chr12:38,581,457...38,824,712
|
|
G |
FASN |
fatty acid synthase |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of FASN mRNA MLXIP protein affects the reaction [Glucose results in increased expression of FASN mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr12:922,405...937,560
Ensembl chr12:920,509...937,561
|
|
G |
INS |
insulin |
multiple interactions increases transport |
EXP |
INS protein promotes the reaction [AZ 002 results in increased uptake of Glucose]; oxophenylarsine inhibits the reaction [INS protein results in increased transport of Glucose]; Sirolimus inhibits the reaction [Glucose results in increased secretion of INS protein] |
CTD |
PMID:8048502 PMID:8699633 PMID:20622751 |
|
NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
|
|
G |
LOC102165256 |
V-type proton ATPase subunit G 1 pseudogene |
decreases expression |
EXP |
Glucose results in decreased expression of ATP6V1G1 mRNA |
CTD |
PMID:16313995 |
|
NCBI chr 7:19,272,032...19,272,926
|
|
G |
MLXIP |
MLX interacting protein |
multiple interactions increases expression |
EXP |
Glucose promotes the reaction [T0901317 results in increased expression of MLXIP mRNA]; MLXIP protein affects the reaction [Glucose results in increased expression of ACACA mRNA]; MLXIP protein affects the reaction [Glucose results in increased expression of FASN mRNA]; MLXIP protein affects the reaction [Glucose results in increased expression of SREBF1 mRNA] Glucose results in increased expression of MLXIP mRNA |
CTD |
PMID:25827716 |
|
NCBI chr14:30,575,098...30,646,275
Ensembl chr14:30,577,661...30,646,243
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
EXP |
Kangen-karyu inhibits the reaction [Glucose results in increased expression of NOS2 protein] |
CTD |
PMID:16949779 |
|
NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of NR1H3 mRNA T0901317 promotes the reaction [Glucose results in increased expression of NR1H3 mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr 2:15,315,283...15,336,785
Ensembl chr 2:15,315,282...15,334,820
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
Kangen-karyu inhibits the reaction [Glucose results in increased expression of PTGS2 protein] |
CTD |
PMID:16949779 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
SLC2A1 |
solute carrier family 2 member 1 |
increases transport |
EXP |
SLC2A1 protein results in increased transport of Glucose |
CTD |
PMID:12081571 |
|
NCBI chr 6:168,535,398...168,561,170
Ensembl chr 6:168,535,440...168,560,867
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
increases expression multiple interactions |
EXP |
Glucose results in increased expression of SREBF1 mRNA MLXIP protein affects the reaction [Glucose results in increased expression of SREBF1 mRNA] |
CTD |
PMID:25827716 |
|
NCBI chr12:60,733,967...60,750,951
Ensembl chr12:60,733,907...60,751,267
|
|
|
G |
ALPL |
alkaline phosphatase, biomineralization associated |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA |
CTD |
PMID:30481989 |
|
NCBI chr 6:79,589,695...79,649,646
Ensembl chr 6:79,589,045...79,649,644
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:30481989 |
|
NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
[Troglitazone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CASP3 mRNA |
CTD |
PMID:30481989 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CEBPA |
CCAAT enhancer binding protein alpha |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 6:43,083,200...43,085,884
Ensembl chr 6:43,083,207...43,085,836
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA |
CTD |
PMID:30481989 |
|
NCBI chr12:26,379,087...26,397,180
Ensembl chr12:26,379,090...26,397,004
|
|
G |
CTNNB1 |
catenin beta 1 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr13:25,163,550...25,208,314
Ensembl chr13:25,164,277...25,208,311
|
|
G |
FABP4 |
fatty acid binding protein 4 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,896
|
|
G |
IGF1 |
insulin like growth factor 1 |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,033
|
|
G |
IGF1R |
insulin like growth factor 1 receptor |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 1:137,383,623...137,691,038
Ensembl chr 1:137,387,825...137,691,058
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA |
CTD |
PMID:30481989 |
|
NCBI chr 7:40,106,581...40,353,304
Ensembl chr 7:40,106,532...40,460,687
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
|
|
|
G |
IL18 |
interleukin 18 |
multiple interactions |
EXP |
mogroside V inhibits the reaction [Particulate Matter results in increased expression of IL18 mRNA] |
CTD |
PMID:35134483 |
|
NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
increases expression |
EXP |
mogroside V results in increased expression of IL1B mRNA |
CTD |
PMID:35134483 |
|
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions |
EXP |
mogroside V inhibits the reaction [Particulate Matter results in increased expression of NLRP3 protein] |
CTD |
PMID:35134483 |
|
NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
mogroside V inhibits the reaction [Particulate Matter results in increased expression of NOS2 mRNA] |
CTD |
PMID:35134483 |
|
NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
mogroside V inhibits the reaction [Particulate Matter results in increased expression of PTGS2 mRNA] |
CTD |
PMID:35134483 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
mogroside V inhibits the reaction [Particulate Matter results in increased phosphorylation of RELA protein] |
CTD |
PMID:35134483 |
|
NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
mogroside V inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA] |
CTD |
PMID:35134483 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
SLC5A1 |
solute carrier family 5 member 1 |
decreases expression |
EXP |
Neomycin results in decreased expression of SLC5A1 mRNA; Neomycin results in decreased expression of SLC5A1 protein |
CTD |
PMID:12927799 |
|
NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841
|
|
|
G |
IL10 |
interleukin 10 |
decreases expression |
EXP |
notoginsenoside R1 results in decreased expression of IL10 protein |
CTD |
PMID:25721049 |
|
NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,728...67,405,378
|
|
G |
IL4 |
interleukin 4 |
decreases expression |
EXP |
notoginsenoside R1 results in decreased expression of IL4 protein |
CTD |
PMID:25721049 |
|
NCBI chr 2:134,986,817...134,994,365
Ensembl chr 2:134,986,817...134,994,365
|
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions |
EXP |
tilmicosin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; tilmicosin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid] |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|
|
G |
CYP3A29 |
cytochrome P450 family 3 subfamily A member 29 |
multiple interactions |
EXP |
Troleandomycin inhibits the reaction [CYP3A29 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Troleandomycin inhibits the reaction [CYP3A29 protein results in increased hydroxylation of Testosterone]; Troleandomycin inhibits the reaction [CYP3A29 protein results in increased oxidation of Nifedipine] |
CTD |
PMID:20863320 |
|
NCBI chr 3:6,738,502...6,778,121
Ensembl chr 3:6,738,486...6,778,944
|
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions |
EXP |
Tylosin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Tylosin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid] |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|